Abstract:
The present invention discloses (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane, salts thereof, and its use to treat pain and other disorders associated with the nicotinic acetylcholine receptor.
Abstract:
Disclosed is a salt of (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane, selected from the group consisting of acetate, citrate, fumarate, hemicitrate, hydrocholoride, maleate, methanesulfonate, 4-methylbenzenesulfonate, sulphate, L-tartrate and trifluoroacetate. Also disclosed is a process for preparing a compound of formula (5J) comprising the steps of a) treating compound (5D), with an aqueous acid; b) treating the mixture from step (a) with a compound of formula (A), wherein R2 is phenyl optionally substituted with alkyl, alkoxy or halo in the presence of magnesium bromide in a mixture of isopropyl alcohol and dichloromethane to provide a compound of formula (B), c) using the compound of formula (B) to prepare the compound (5J).
Abstract:
Disclosed is a pharmaceutical composition for treating amyotrophic lateral sclerosis or premenstrual syndrome which comprises a therapeutically effective amount of (1S,5S)-3-(5,6-dichloro-pyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane or a pharmaceutically acceptable salt thereof. Further disclosed is a pharmaceutical composition comprising a therapeutically effective amount of (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier, wherein the composition is in a solid dosage form or a liquid dosage form. Also disclosed is (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane (L)-tartrate and (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane p-toluenesulfonate.
Abstract:
The present invention discloses (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane and its use to treat pain and other disorders associated with the nicotinic acetylcholine receptor.
Abstract:
The present invention discloses (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane, salts thereof, and its use to treat pain and other disorders associated with the nicotinic acetylcholine receptor.
Abstract:
The present invention discloses (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane and its use to treat pain and other disorders associated with the nicotinic acetylcholine receptor.